AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22340282 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod 5% cream
Number of subjects: 61
Study 20441691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 785
Study 17276575 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation in a flying helicopter
Number of subjects: 11
Study 17276575 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation in a moving ambulance
Number of subjects: 11
Study 17276575 — intervention group
Group type: COMPARATOR
Intervention: Resuscitation at the scene
Number of subjects: 11
Study 15934987 — intervention group
Group type: EXPERIMENTAL
Intervention: PLTs pooled before storage
Number of subjects: 23
Study 15934987 — intervention group
Group type: COMPARATOR
Intervention: PLTs stored individually
Number of subjects: 23
Study 15934987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled storage
Number of subjects: 23
Study 15934987 — intervention group
Group type: COMPARATOR
Intervention: Routine storage
Number of subjects: 23
Study 12000378 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine for 6 weeks
Number of subjects: 134
Study 12000378 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine for 8 weeks
Number of subjects: 134
Study 12000378 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin (20 mg x kg(‐1) x day(‐1)) for 12 weeks
Number of subjects: 134
Study 9549823 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete case analysis (MCAR)
Number of subjects: 0
Study 9549823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-effects models (MAR)
Number of subjects: 0
Study 9549823 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mixed-effects and survival model
Number of subjects: 0
Study 9549823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-mixture model
Number of subjects: 0
Study 7789675 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinyl bougies (Savary type)
Number of subjects: 34
Study 7789675 — intervention group
Group type: EXPERIMENTAL
Intervention: Through-the-scope balloons
Number of subjects: 34
Study 2281807 — intervention group
Group type: EXPERIMENTAL
Intervention: Fengabine
Number of subjects: 0
Study 2281807 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 0
Study 6802779 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB) at doses ranging from 0.5 to 1.5 mg/kg/day and from 1.6 to 2.5 mg/kg/day
Number of subjects: 90
Study 6802779 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of Phenobarbital (PB)
Number of subjects: 90
Study 31642352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise training (1-hour sessions, 3 times weekly for 12 weeks)
Number of subjects: 164
Study 31642352 — intervention group
Group type: COMPARATOR
Intervention: Low-dose exercise training (1-hour sessions, 2 times weekly for 8 weeks)
Number of subjects: 164
Study 30992293 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief support (HP-led 10 min consultation and written self-help guide)
Number of subjects: 112
Study 30992293 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief support plus shopping feedback (same HP-led support plus personalized feedback based on grocery store loyalty card data)
Number of subjects: 112
Study 30992293 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 112
Study 28515107 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU/day vitamin D3
Number of subjects: 405
Study 28515107 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU/day vitamin D3
Number of subjects: 405
Study 28515107 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 IU/day vitamin D3
Number of subjects: 405
Study 28515107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 25894912 — intervention group
Group type: EXPERIMENTAL
Intervention: TaperGuard ETT (group T)
Number of subjects: 58
Study 25894912 — intervention group
Group type: COMPARATOR
Intervention: Conventional ETT (group C)
Number of subjects: 58
Study 23945130 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-IPT (25 mg of sulfadoxine and 1.25 mg of pyrimethamine)
Number of subjects: 0
Study 23945130 — intervention group
Group type: COMPARATOR
Intervention: Daily co-trimoxazole doses (960 mg per dose)
Number of subjects: 0
Study 21860922 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils (EOs) mouthrinse
Number of subjects: 142
Study 21860922 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 142
Study 21860922 — intervention group
Group type: COMPARATOR
Intervention: Negative control rinse
Number of subjects: 142
Study 19487941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 150
Study 19487941 — intervention group
Group type: COMPARATOR
Intervention: Intravenous digoxin
Number of subjects: 150
Study 19487941 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amiodarone
Number of subjects: 150
Study 16718797 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day quadruple therapy (omeprazole 20 mg, amoxicillin 1 g, furazolidone 200 mg, colloidal bismuth subcitrate 220 mg four times for one day)
Number of subjects: 60
Study 16718797 — intervention group
Group type: COMPARATOR
Intervention: Seven-day triple therapy (omeprazole 40 mg, amoxycillin 1 g, furazolidone 100 mg, all twice a day for 7 days)
Number of subjects: 60
Study 15310638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 30 microg
Number of subjects: 50
Study 11318078 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate ophthalmic gel-forming solution (timolol GS) once daily
Number of subjects: 286
Study 11318078 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol solution twice daily
Number of subjects: 286
Study 9542556 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural tramadol 20 mg
Number of subjects: 40
Study 9542556 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural tramadol 100 mg
Number of subjects: 40
Study 9542556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8138772 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3581680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine and carbacholine
Number of subjects: 22
Study 3581680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atropine and pilocarpine
Number of subjects: 22
Study 3581680 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine, scopolamine, metacine or chlorosyle (inducing 'paradoxical' salivation)
Number of subjects: 22
Study 3581680 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous secretion
Number of subjects: 22
Study 3581680 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflex secretion (partially restored)
Number of subjects: 22
Study 3581680 — intervention group
Group type: EXPERIMENTAL
Intervention: Denervated glands
Number of subjects: 22
Study 30525740 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% self-prepared hypertonic nasal saline irrigation (1.8% SPHNSI)
Number of subjects: 78
Study 30525740 — intervention group
Group type: COMPARATOR
Intervention: 0.9% commercial isotonic nasal saline irrigation (0.9% CINSI)
Number of subjects: 78
Study 30525740 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% SPHNSI and 0.9% CINSI
Number of subjects: 78
Study 29729169 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 90
Study 29729169 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor (omega-3 polyunsaturated fatty acids) 2 capsules (1680 mg) for one month along with standard treatment
Number of subjects: 90
Study 27566551 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sea fish oil (0.2 ml/Kg bodyweight/day)
Number of subjects: 77
Study 27566551 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (0.2 ml/Kg bodyweight/day)
Number of subjects: 77
Study 26599957 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) treatment
Number of subjects: 30
Study 26599957 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 30
Study 22423115 — intervention group
Group type: EXPERIMENTAL
Intervention: Line drawings of tools as prime stimuli
Number of subjects: 0
Study 22423115 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-elongated tool pictures as prime stimuli
Number of subjects: 0
Study 22423115 — intervention group
Group type: EXPERIMENTAL
Intervention: Elongated stick-like rectangles as prime stimuli
Number of subjects: 0
Study 22423115 — intervention group
Group type: EXPERIMENTAL
Intervention: Elongated vegetables as prime stimuli
Number of subjects: 0
Study 22423115 — intervention group
Group type: EXPERIMENTAL
Intervention: Stubby vegetables as prime stimuli
Number of subjects: 0
Study 22423115 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotated elongated stick-like rectangles, diamond shapes, and cut circles as prime stimuli
Number of subjects: 0
Study 21086592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesotherapy (MT) and Electro-stimulation (EMS)
Number of subjects: 60
Study 21086592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 18242486 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-rest sestamibi SPECT imaging with physical exercise (n = 573)
Number of subjects: 1006
Study 18242486 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-rest sestamibi SPECT imaging with dipyridamole (n = 433)
Number of subjects: 1006
Study 15951544 — intervention group
Group type: EXPERIMENTAL
Intervention: Retarded release phosphatidylcholine (6 g daily for three months)
Number of subjects: 60
Study 15951544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12034943 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 430
Study 12034943 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopy
Number of subjects: 430
Study 10505588 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 0
Study 10505588 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 7558547 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation of living wills in the treatment group
Number of subjects: 200
Study 7558547 — intervention group
Group type: COMPARATOR
Intervention: Preparation of living wills in the control group
Number of subjects: 200
Study 7558547 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-sustaining treatment decisions in the treatment group
Number of subjects: 200
Study 7558547 — intervention group
Group type: COMPARATOR
Intervention: Life-sustaining treatment decisions in the control group
Number of subjects: 200
Study 1782304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg orally
Number of subjects: 25
Study 1782304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 358369 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 50
Study 358369 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy with pyloroplasty (SV +P)
Number of subjects: 50
Study 31701378 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignettes about women with underweight BMI
Number of subjects: 295
Study 31701378 — intervention group
Group type: COMPARATOR
Intervention: Vignettes about women with average weight BMI
Number of subjects: 295
Study 31701378 — intervention group
Group type: COMPARATOR
Intervention: Vignettes about women with overweight BMI
Number of subjects: 295
Study 31221221 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 437
Study 31221221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 28101565 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation + conventional physical therapy
Number of subjects: 25
Study 28101565 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (sham neuromuscular electrical stimulation + conventional physical therapy)
Number of subjects: 25
Study 26468173 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric massage in Group A
Number of subjects: 40
Study 26468173 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) without isometric massage
Number of subjects: 40
Study 23813878 — intervention group
Group type: EXPERIMENTAL
Intervention: PACI‐O (Personal Aspirations and Concerns Inventory for Offenders)
Number of subjects: 37
Study 23813878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PACI‐O)
Number of subjects: 37
Study 20718944 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ(9) ‐THC (10 mg in IBS patients, 5 and 10 mg in healthy volunteers)
Number of subjects: 22
Study 20718944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19794261 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean isoflavones
Number of subjects: 0
Study 17096160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (Hfx) RTx with concurrent TPF CTx
Number of subjects: 50
Study 17096160 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (Cfx) RTx with concurrent TPF CTx
Number of subjects: 50
Study 15190136 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of ondansetron
Number of subjects: 5199
Study 15190136 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of dexamethasone
Number of subjects: 5199
Study 15190136 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg of droperidol
Number of subjects: 5199
Study 15190136 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 5199
Study 15190136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen
Number of subjects: 5199
Study 15190136 — intervention group
Group type: COMPARATOR
Intervention: Volatile anesthetic
Number of subjects: 5199
Study 15190136 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 5199
Study 15190136 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 5199
Study 15190136 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 5199
Study 11296071 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic medicine consultations for oncology patients
Number of subjects: 70
Study 11296071 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic medicine consultations for symptom management
Number of subjects: 70
Study 11296071 — intervention group
Group type: EXPERIMENTAL
Intervention: Questions about specific therapies
Number of subjects: 70
Study 9488591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beta-carotene
Number of subjects: 1805
Study 9488591 — intervention group
Group type: COMPARATOR
Intervention: History of one or more previous SCCs
Number of subjects: 1805
Study 9488591 — intervention group
Group type: COMPARATOR
Intervention: Multiple prior BCCs
Number of subjects: 1805
Study 9488591 — intervention group
Group type: COMPARATOR
Intervention: Previous SCC or multiple BCC
Number of subjects: 1805
Study 8157190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (regimen A)
Number of subjects: 17
Study 8157190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with 5-FU infusion (regimen B)
Number of subjects: 17
Study 8157190 — intervention group
Group type: COMPARATOR
Intervention: Both regimens A and B
Number of subjects: 17
Study 8157190 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with cisplatin
Number of subjects: 17
Study 8157190 — intervention group
Group type: COMPARATOR
Intervention: Entire group
Number of subjects: 17
Study 8157190 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with microscopic metastasis
Number of subjects: 17
Study 8157190 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with macroscopic metastasis
Number of subjects: 17
Study 3047855 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 136
Study 30144995 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF < 25%
Number of subjects: 19740
Study 30144995 — intervention group
Group type: COMPARATOR
Intervention: LVEF > 35%
Number of subjects: 19740
Study 27979724 — intervention group
Group type: EXPERIMENTAL
Intervention: NEJM video
Number of subjects: 30
Study 27979724 — intervention group
Group type: COMPARATOR
Intervention: Didactic teaching session
Number of subjects: 30
Study 25527767 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND)
Number of subjects: 56
Study 25527767 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 56
Study 23949277 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based technologies coupled with teleassistance service (HBTec-TS)
Number of subjects: 96
Study 23949277 — intervention group
Group type: COMPARATOR
Intervention: No home-based technologies (control group)
Number of subjects: 96
Study 21248359 — intervention group
Group type: EXPERIMENTAL
Intervention: Living cellular constructs (LCC)
Number of subjects: 44
Study 21248359 — intervention group
Group type: COMPARATOR
Intervention: Autogenous free gingival grafts
Number of subjects: 44
Study 18282805 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin
Number of subjects: 305
Study 18282805 — intervention group
Group type: COMPARATOR
Intervention: S-1 alone
Number of subjects: 305
Study 17408818 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb aerosol
Number of subjects: 0
Study 17408818 — intervention group
Group type: COMPARATOR
Intervention: Schwarz subcutaneous
Number of subjects: 0
Study 17408818 — intervention group
Group type: COMPARATOR
Intervention: Edmonston-Zagreb subcutaneous
Number of subjects: 0
Study 15131566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine (4%, 100 mg) 4 times daily for 8 weeks
Number of subjects: 50
Study 15131566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) 4 times daily for 8 weeks
Number of subjects: 50
Study 11176555 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil questionnaire administration
Number of subjects: 134
Study 11176555 — intervention group
Group type: COMPARATOR
Intervention: Computer administration
Number of subjects: 134
Study 9023171 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 325
Study 9023171 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 325
Study 7932392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute vasopressin
Number of subjects: 64
Study 7932392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 3124478 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 and folic acid treatment for 3 months
Number of subjects: 17
Study 3124478 — intervention group
Group type: COMPARATOR
Intervention: Untreated similar patients
Number of subjects: 17
Study 30880747 — intervention group
Group type: EXPERIMENTAL
Intervention: NACCRT (Neoadjuvant Concurrent Chemoradiotherapy)
Number of subjects: 39
Study 28201598 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon GH (0.14 mg GH/kg/wk)
Number of subjects: 53
Study 28201598 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon GH (0.21 mg GH/kg/wk)
Number of subjects: 53
Study 28201598 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon GH (0.30 mg GH/kg/wk)
Number of subjects: 53
Study 28201598 — intervention group
Group type: COMPARATOR
Intervention: Genotropin (0.03 mg GH/kg/d)
Number of subjects: 53
Study 25840599 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus/tacrolimus
Number of subjects: 0
Study 25840599 — intervention group
Group type: COMPARATOR
Intervention: methotrexate/tacrolimus
Number of subjects: 0
Study 24412161 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary angiography
Number of subjects: 3981
Study 24412161 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary reperfusion
Number of subjects: 3981
Study 24412161 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypothermia
Number of subjects: 3981
Study 23208159 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet (WL) with caloric restriction of 500 kcal/day for 16 weeks
Number of subjects: 34
Study 23208159 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet plus resistance training (WL+RT) with caloric restriction of 500 kcal/day and 16-week resistance training (2 sessions per week)
Number of subjects: 34
Study 23208159 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 34
Study 19015206 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 4 weeks
Number of subjects: 220
Study 19015206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 17468442 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization transfer imaging (MTR) in affected optic nerves
Number of subjects: 25
Study 17468442 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual evoked potential (VEP) latency measurements
Number of subjects: 25
Study 17468442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion-only MTR measurements
Number of subjects: 25
Study 17468442 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for retinal neuroaxonal loss
Number of subjects: 25
Study 17468442 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 controls)
Number of subjects: 25
Study 15947332 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (125 microg/m2) for 72 hours
Number of subjects: 40
Study 15947332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12034158 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg bid)
Number of subjects: 3029
Study 12034158 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (50 mg bid)
Number of subjects: 3029
Study 11913407 — intervention group
Group type: EXPERIMENTAL
Intervention: CE + MPA 2.5 mg
Number of subjects: 525
Study 11913407 — intervention group
Group type: EXPERIMENTAL
Intervention: CE + MPA 5 mg
Number of subjects: 525
Study 11913407 — intervention group
Group type: EXPERIMENTAL
Intervention: CE + MPA 5 mg (last 14 cycle days)
Number of subjects: 525
Study 11913407 — intervention group
Group type: EXPERIMENTAL
Intervention: CE + MPA 10 mg (last 14 cycle days)
Number of subjects: 525
Study 11913407 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed CE regimen
Number of subjects: 525
Study 11913407 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching tablets)
Number of subjects: 525